In contrast, although HCC first-line drug Sora treatment also delayed tumor growth and reduced tumor vessel density in mice, it failed to normalize tumor vessels, as shown by no difference in pericyte coverage of tumor vessels and enhanced intratumoral hypoxia, and thereby led to decreased CD8+ T cells infiltration (Fig. 9a, Supplementary Fig. 12c–e). This evidence concerns the gene CD8A and hepatocellular carcinoma.